Ultralife (ULBI)
NASDAQ:ULBI
Want to see ULBI full AI Analyst Report?
Earnings Data
Report Date
Jul 23, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
―Last Year’s EPS
0.05Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call delivered a mixed message: near-term financial performance was negatively impacted by lower revenue, significant margin compression and a number of one-time operational disruptions that produced an operating and net loss in Q1. Offsetting these near-term headwinds are a record and growing backlog, multiple product wins and development milestones (including the conformal wearable battery and validated 19 amp cell), progress on vertical integration via the Electrochem acquisition, and continued investments in production capacity and leadership meant to drive margin recovery. Given the sizable operational and profitability issues reported for the quarter but meaningful forward-looking backlog and product progress, the tone is balanced between concern for short-term execution and cautious optimism for future revenue capture.Company Guidance
Record Backlog
Total backlog exited Q1 at $115.1 million, a $20.1 million or 21.1% increase year-over-year; backlog includes over $12 million from products released within the last year and represents 61% of trailing 12-month sales.
Notable Product Wins and Development Milestones
Shipped first order of conformal wearable battery with a backlog in excess of $8 million; 19 amp final cell passed performance validation testing; received a $4 million multiyear award for a universal vehicle adapter; multiple orders for a new 20-watt amplifier and prototype/qualification activity across wearable AI compute, Strike Hub, thin cell medical applications and other OEM projects.
Vertical Integration Progress and Commercialization Potential
Electrochem acquisition enabling increased internal cell use — management expects to more than double use of in-house cells in internal packs this year as customer qualifications are completed, expanding addressable pack assembly market and supporting margin improvement initiatives.
Adjusted EBITDA (TTM) and Liquidity Position
Adjusted EBITDA for the quarter was $3.2 million (6.8% of sales) and trailing twelve-month adjusted EBITDA was $15 million (8% of sales); ended Q1 with working capital of $67.1 million and a current ratio of 2.6, indicating a solid near-term liquidity position.
Operational Investments and Leadership Actions
Added and trained direct labor at Random and Newark to support increased demand, installed new experienced plant leadership in both sites, and invested in product development and brand realignment under the Ultralife master brand to strengthen go-to-market clarity.
ULBI Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ULBI Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 08, 2026 | $7.05 | $5.97 | -15.32% |
Jan 29, 2026 | $6.40 | $6.47 | +1.09% |
Nov 18, 2025 | $5.54 | $5.05 | -8.84% |
Aug 07, 2025 | $8.16 | $6.77 | -17.03% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Ultralife (ULBI) report earnings?
Ultralife (ULBI) is schdueled to report earning on Jul 23, 2026, Before Open (Confirmed).
What is Ultralife (ULBI) earnings time?
Ultralife (ULBI) earnings time is at Jul 23, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ULBI EPS forecast?
Currently, no data Available